Palivizumab (Synagis; MedImmune/Abbott) is a humanized murine monoclonal antibody against the RSV fusion protein that prevents the spread of virus to the lower respiratory tract 2. It was approved ...

Pharmac has announced that, from January 1 2025, it will fund palivizumab - a medicine that prevents serious illness from ...

Background: Since its introduction, palivizumab has been used to prevent respiratory syncytial virus (RSV) infection in high-risk populations. Recommendations for palivizumab administration ...

A breast cancer drug - which keeps the disease stable for up to four times longer than the previous treatment - will be publicly funded from next month.

Pharmac will also fund osimertinib for people with a type of advanced non-small cell lung cancer. About 20 percent of people with non-small cell lung cancer have a mutation in their cancer that can be ...

High levels of neutralizing antibodies to RSV F protein have been shown to correlate with protection from RSV disease in infants and the elderly, and the clinical effectiveness of palivizumab and ...

Palivizumab, also known by the brand name Synagis, which is used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk children, was launched ...